Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1

Conditions

Myasthenia Gravis 4Neoplasms, Plasma Cell 3Neoplasms 3Multiple Myeloma 2Lymphoma 2Leukemia 2Infections 2Hematologic Neoplasms 2Urologic Neoplasms 1Neuromyelitis Optica 1Neuroblastoma 1Myelitis, Transverse 1Melanoma 1Lymphoma, Non-Hodgkin 1Limbic Encephalitis 1Immunoglobulin Light-chain Amyloidosis 1Epilepsy 1Epilepsies, Partial 1Drug Resistant Epilepsy 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Autoimmune Diseases of the Nervous System 1Autoimmune Diseases 1

Interventions

Cyclophosphamide 87fludarabine 74Tacrolimus 45fludarabine phosphate 44Mycophenolic Acid 42Whole-Body Irradiation 41Busulfan 35Melphalan 31Antilymphocyte Serum 24thymoglobulin 22Methotrexate 22Rituximab 21venetoclax 20Standard of Care 20Sirolimus 20Azacitidine 20Thiotepa 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 16Cytarabine 16Nivolumab 15Filgrastim 15Dexamethasone 14Cyclosporine 13Bortezomib 13Mesna 12Peripheral Blood Stem Cell Transplantation 11trametinib 10Specimen Handling 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Hematologic Neoplasms × Immunoglobulins, Intravenous × Clear all
NCT04438382 2026-06-02

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Eastern Cooperative Oncology Group

Phase 2 Terminated
1 enrolled 1 chart
Other hematologic neoplasm

Hematologic Neoplasms

NCT04634435 2025-01-20

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

Biohaven Pharmaceuticals, Inc.

Phase 1 Completed
7 enrolled
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡